{"id":"W4396599757","doi":"10.1158/1538-7445.sabcs23-ps17-06","title":"Abstract PS17-06: A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"York University","funders":"","keywords":"Fulvestrant; Medicine; Estrogen receptor; Internal medicine; Estrogen; Oncology; Cancer; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006223586,0.0003129806,0.0006430632,0.0003889484,0.0000787328,0.0000682268,0.0001914316,0.00007997736,0.0002503758],"category_scores_gemma":[0.00008560155,0.0001802157,0.00006176701,0.001269858,0.0008290303,0.0003292106,0.00007875581,0.0009123936,0.000003214166],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001066451,"about_ca_system_score_gemma":0.001310366,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003083607,"about_ca_topic_score_gemma":0.002299583,"domain_scores_codex":[0.9968852,0.0003088826,0.000538666,0.000616197,0.001086837,0.0005641594],"domain_scores_gemma":[0.9983501,0.0003979222,0.0001702936,0.0003099115,0.00060557,0.000166156],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5938439,0.005920642,0.08311782,0.002215201,0.001409562,0.000413868,0.01656018,0.0001283789,0.009516003,0.0002022924,0.0003608901,0.2863112],"study_design_scores_gemma":[0.306239,0.01451024,0.6196814,0.02092695,0.0002965828,0.00008396334,0.005079148,0.0001737685,0.03149853,0.0003238019,0.0004577479,0.000728844],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992762,0.0009279791,0.00001718177,0.001537438,0.0001608101,0.003888618,0.0006330138,0.00002616637,0.00004680746],"genre_scores_gemma":[0.998115,0.000187577,0.0001252227,0.00005878588,0.0001095396,0.001122855,0.00003330513,0.00007250612,0.0001752049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5365636,"threshold_uncertainty_score":0.7348982,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03390940358316925,"score_gpt":0.3827888557235882,"score_spread":0.3488794521404189,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}